Larimar Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Operating expenses | $172.5M | $90.9M | $41.8M | $36.5M | $50.5M |
| Cash from operations | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Capital expenditure | $91,000 | $515,000 | $164,000 | $100,000 | $333,000 |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
Shares outstanding 103.9M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.